|
30.1.2017 |
EN |
Official Journal of the European Union |
C 30/40 |
Appeal brought on 28 November 2016 by Merck KGaA against the judgment of the General Court (Ninth Chamber) delivered on 8 September 2016 in Case T-470/13: Merck KGaA v European Commission
(Case C-614/16 P)
(2017/C 030/44)
Language of the case: English
Parties
Appellant: Merck KGaA (represented by: B. Bär-Bouyssière, Rechtsanwalt, S. Smith, Solicitor, R. Kreisberger, Barrister, D. Mackersie, Advocate)
Other parties to the proceedings: European Commission, Generics (UK) Ltd
Form of order sought
The appellant claims that the Court should:
|
— |
Set aside paragraph 1 of the operative part of the Judgment; |
|
— |
annul Articles 1(1), 2(1) of the Decision and Articles 3 and 4 insofar as these are addressed to Merck; |
|
— |
in the alternative, annul or reduce the penalty imposed on Merck; |
|
— |
set aside paragraph 2 of the operative part of the Judgment and order the Commission to bear their own costs and to pay the costs of Merck, relating to both the proceedings at first instance and to this appeal. |
Pleas in law and main arguments
|
1. |
The Appellant’s first ground of appeal is that the General Court erred in law by finding that the patent settlement agreements (‘PSAs’), concluded between Generics (UK) (‘GUK’) and Lundbeck, were restrictions by object under Article 101(1) TFEU:
|
|
2. |
The Appellant’s second ground of appeal is that the General Court erred in law by concluding that GUK and Lundbeck were potential competitors at the time when the PSAs were concluded:
|
|
3. |
The Appellant’s third ground of appeal is that the General Court erred in law by upholding the fine imposed by the Commission on the Appellant:
|